Status and phase
Conditions
Treatments
About
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 1 patient group
Loading...
Central trial contact
Treeline Clinical Operations
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal